Samsung Biologics has struck a high-impact partnership with Eli Lilly and Company to bring a new Lilly Gateway Labs site to South Korea—marking a significant push to accelerate early-stage biotech innovation in Asia.

 

The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms. Designed with flexible lab space, advanced research infrastructure, and collaborative environments, the five-story, 125,000-square-foot hub is expected to open by July 2027.

 

The new site will act as a critical bridge between discovery and manufacturing, helping startups translate cutting-edge science into viable therapies. Samsung Biologics will oversee development and operations, while Lilly will provide hands-on scientific support and global expertise through its Gateway Labs platform.

 

Beyond individual companies, the project aims to transform South Korea into a global magnet for biotech innovation—drawing international talent, boosting research capabilities, and strengthening the nation’s standing in life sciences.

 

The Gateway Labs model has already proven its impact. Since launching in 2019, participating companies have raised over $3 billion and advanced more than 50 therapeutic programs, backed by Lilly Catalyze360.

 

“This collaboration represents a significant step in expanding Gateway Labs' global reach,” said Julie Gilmore, vice president, and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management. 

 

“Korea has emerged as a vibrant center for life sciences innovation with exceptional scientific talent. By establishing Gateway Labs here, we're creating a hub where early-stage companies can access the resources, expertise, and connections needed to accelerate their journey from discovery to development, strengthening both local and global biotech innovation.”

 

Samsung Biologics CEO John Rim emphasized the long-term vision behind the move: “The initiative reflects Samsung Biologics' long-term commitment to advancing innovation across the healthcare ecosystem. 

 

"By establishing a global open innovation platform in Korea in collaboration with Lilly's Gateway Labs network, we aim to strengthen the foundation of the domestic bio-industry while connecting it more deeply with the global innovation network. Through this platform, we are creating an environment where promising scientific innovations can progress into new lifesaving therapies, supporting sustainable industry growth, enhanced patient care."